Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194004 | 0.87 | GCK (0.36) | GCKNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL3181981 | 0.84 | GPR35 (0.41) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3379022 | 0.83 | GCK (0.51) | GCKCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL3182630 | 0.82 | GCK (0.36) | GCKNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL3378923 | 0.82 | GCK (0.47) | GCKCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL3183828 | 0.81 | GCK (0.38) | GCKNPC1RAB9AMAPK1SMN1; SMN2 | |
| SCHEMBL3191740 | 0.80 | PIP4K2C (0.60) | GCK | |
| SCHEMBL3186655 | 0.78 | GRM5 (0.47) | CYP2E1CYP3A4CYP2A6CYP2C9CYP2B6 | |
| SCHEMBL3175014 | 0.77 | CCNK (0.41) | GCKCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL3262846 | 0.75 | GRM5 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | claimed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | claimed |
| US-7659401-B2 | N-(2-methyl-7-pyridin-3-yl-thiazolo[4,5-c]pyridin-4-yl)-N-(2(4)-methyl-thiazol-4(2)-yl)-amine; metabotropic glutamate receptor antagonists; mGluR5 receptor mediated disorders; nervous system disorders; analgesics; incontinence; liver disorders; obesity; Fragile x syndrome; autism;Alzeimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2010-02-09 | — | — | US | disclosed |
| EP-1948667-A2 | THIAZOLO[4,5-C]PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007054436-A2 | THIAZOLO [4 , 5-C] PYRIDINE DERIVATIVES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105891-A1 | Thiazole[4,5-C]pyridine derivatives | GRM5, GRIK5, GRM1 | GCK 1274/4885CYP2E1 1911/4885CYP3A4 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.